KOSDAQBiotech & Pharma445680

Curiox Biosystems

₩46,250▲ 3.58%2026-11-18 close
Market Cap
₩796.6B
Turnover
₩5B
Volume
100K
Shares out.
17.2M
PER
—
PBR
18.6×
EPS
-₩863
Dividend Yield
0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q4–2026Q3) · Dividend yield is based on ₩0 per share · Prices as of the 2026-11-18 close

01

Report overview

From instruments to software: whether the loss structure can turn

Curiox Biosystems is trying to shift revenue from cell-prep instruments toward software licenses, but disclosed operating losses have continued through the third quarter of 2026.

  1. 1

    2025 revenue rose 12.3% year on year to KRW 5.15 billion, but the operating loss of KRW 12.3 billion and net loss of KRW 27.2 billion show the loss structure remains.

  2. 2

    The company cited a larger derivative valuation loss, tied to the rise in its share price and linked to convertible bond rights, as the main reason for the wider 2025 net loss.

  3. 3

    Third-quarter 2026 revenue of KRW 1.49 billion rose 7.8% year on year, while the net loss attributable to controlling shareholders widened to KRW 5.31 billion.

  4. 4

    A comprehensive Pluto Code software license was signed with a global pharmaceutical company in April 2026, and the company has set a target for software to outweigh instruments within three years.

  5. 5

    On November 12, 2026, the company disclosed a lawsuit against Becton, Dickinson and Company and Waters Corporation over C-FREE-related technology, adding an uncertainty factor.

02

Business structure

Curiox Biosystems is a bioinstrument company that sells automated cell pretreatment instruments and consumables based on its centrifuge-free cell washing technology, C-FREE. The company was founded in September 2018 and listed on KOSDAQ in August 2023.

Its product line widened from Pluto LT (June 2024) to Venus HT (August 2024), Pluto MT (December 2024), Pluto HT and Pluto Alpha (June 2025), and Pluto Code (August 2025). Based on second-quarter 2026 revenue, the mix was 42% cell pretreatment instruments, 24% other, 21% accessories and 14% plates.

Because instrument sales are a large share, results depend heavily on the timing of instrument sales. Software is the axis the company is using to change this structure.

In April 2026, the company said it signed a comprehensive software license with a large global pharmaceutical company for enterprise deployment of Pluto Code. The company says software carries virtually no manufacturing cost, so the profit it can expect is similar to that of instruments.

The company describes itself as collaborating with 20 of the world's largest biopharma companies and research institutes. Media reported a KRW 500 million order from a global pharma company in August 2026 and a KRW 700 million first order from a global top-five CRO in October.

Its differentiators are the centrifuge-free washing method and standardization work with NIST in the United States.

03

Earnings trend

Quarterly revenue · Operating profit
RevenueOperating profit
Annual revenue · Operating profit
RevenueOperating profit
Quarterly results · Last 5 quarters
QuarterRevenueOperating profitOp. margin
2025Q3₩1.4B-₩2.7B−193.6%
2025Q4₩1.8B-₩2.7B−143.4%
2026Q1₩1.3B-₩3.3B−245.5%
2026Q2₩1.2B-₩4.5B−379.1%
2026Q3₩1.5B-₩3.9B−262.3%
Annual results
YearRevenueOperating profitNet income (parent)Op. marginROEDebt-to-equity
2022₩7.2B-₩11.4B-₩11.5B−157.8%−26.2%10.9%
2023₩6.8B-₩10.6B-₩10B−155.5%−19.0%9.3%
2024₩4.6B-₩13.4B-₩8.1B−291.6%−16.6%45.1%
2025₩5.2B-₩12.3B-₩27.2B−239.0%−51.5%47.8%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-11-17

04

Earnings analysis

On a disclosed basis, annual revenue went from KRW 7.24 billion in 2022 to KRW 6.79 billion in 2023 (down 6.2% year on year) and KRW 4.59 billion in 2024 (down 32.4%), before rising to KRW 5.15 billion in 2025 (up 12.3%). 2022 was the largest year of the four and 2024 the smallest.

Over the same period, operating losses were KRW 11.4 billion in 2022, KRW 10.6 billion in 2023, KRW 13.4 billion in 2024 and KRW 12.3 billion in 2025, with operating margins of -157.8%, -155.5%, -291.6% and -239.0%. The company has reported operating losses in each of the four years from 2022 to 2025.

In 2024 revenue fell while the operating loss widened; in 2025 revenue rose and the operating loss narrowed. Net loss attributable to controlling shareholders went from KRW 11.5 billion in 2022 to KRW 10 billion in 2023 and KRW 8.09 billion in 2024, then widened to KRW 27.2 billion in 2025.

Net loss including non-controlling interests moved in the same direction. The company cited a larger derivative valuation loss, tied to convertible bond rights and the share price rise, as the main reason for the wider 2025 net loss, so that year's result includes a large non-operating valuation component.

Quarterly revenue was KRW 1.32 billion in Q1 2026 and KRW 1.18 billion in Q2 2026, two consecutive declines, before rebounding to KRW 1.49 billion in Q3 2026.

Operating losses widened from KRW 2.68 billion in Q3 2025 to KRW 4.46 billion in Q2 2026 and narrowed to KRW 3.92 billion in Q3 2026, but the Q3 loss was still wider than a year earlier.

The net loss attributable to controlling shareholders was KRW 5.31 billion in Q3 2026 against KRW 3.03 billion in Q3 2025, and the four quarters from Q4 2025 to Q3 2026 total KRW 15.1 billion.

A wisereport aggregation (as of September 7, 2026) shows first-half 2026 revenue up 30.3% year on year and the operating loss up 10.4%. Operating cash flow was negative in all four years, at KRW -9.89 billion, KRW -8.16 billion, KRW -9.7 billion and KRW -11.1 billion.

At the end of 2025, total equity was KRW 52.8 billion, of which the controlling shareholders' stake was the same amount, and total liabilities were KRW 25.2 billion, lifting the debt ratio from 45.1% in 2024 to 47.8%.

05

Industry analysis

The company operates in the market for instruments that automate cell pretreatment in pharmaceutical and biotech labs and production sites. The central issues are reproducibility and standardization of sample preparation for cell analysis.

Kiwoom Securities said at the CYTO 2026 conference in June 2026 that the high reproducibility of its automated instruments showed a possibility of becoming a standard in automated cell pretreatment.

A NIST flow cytometry study in the United States pointed to the need for automated sample preparation, and the company said it joined a follow-up second study. The company also said the standardization trend was confirmed at a symposium held by a national measurement standards institute.

On technology, the centrifuge-free washing method is described as reducing cell damage, and a March 2026 Samsung Securities report emphasized that software compatible with existing workstations can convert them to automation without replacing hardware.

Whether instrument replacement demand and software adoption will translate into earnings quickly is not yet visible in disclosures.

On competition, the differentiators are the centrifuge-free method and standardization research results, and demand for pharma process automation is reflected in the company's statement that it is discussing contracts with several global pharmaceutical companies. The reliance on instrument sales makes quarterly results sensitive to the timing of sales.

06

Outlook

In June 2026, media reported that the company is discussing arrangements with several global pharmaceutical companies and is pursuing additional license agreements before year-end. In the same period, a company official said software is expected to grow to exceed the instrument business within three years.

An August 2026 media report said the company planned to pursue its first partnership with a global instrument maker within the year.

In an August 2026 interview, CEO Kim Nam-yong said the company is discussing instrument adoption with more than ten global pharma companies and that multi-unit contracts with upfront payments equal to 10% or more of prior-year revenue could follow.

These remarks express expectations and do not confirm that any contract has been signed. On November 10, 2026, the company announced a commercial organization and strategic advisory council weighted toward experts from the global instrument industry.

The next checkpoints are how much software license revenue appears in quarterly results and whether the narrowing of operating losses continues after Q3 2026.

The lawsuit disclosed on November 12, 2026 concerns protection of C-FREE technology, and the outcome of the court proceedings could change the operating environment for the technology business. At the March 2026 annual general meeting, shareholders approved charter amendments and the election of outside directors.

07

Valuation

PER
—
PBR
18.6×
ROE
-31.6%
EPS
-₩863
BPS
₩2,408
Dividend per share
₩0

PER cannot be calculated because the last four quarters were all net losses. Price-to-book is therefore the main comparison point, and it sits high against the company's own history.

Market capitalization is far above total equity at the end of 2025, which was KRW 52.8 billion, with the controlling shareholders' stake reported at the same amount. The company pays essentially no dividend, so there is no cash yield to compare on a shareholder-return basis.

Operating losses went from KRW 11.4 billion in 2022 to KRW 12.3 billion in 2025, not a large reduction, and the 2025 net loss was larger. The current multiples should therefore be read alongside the pace at which operating indicators improve.

Valuation interpretation depends on trends in operating margin, the share of software revenue, and the size of derivative valuation gains and losses.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-11-17

08

Bull factors

Shift to software licensing

In April 2026 the company signed a comprehensive Pluto Code license with a large global pharmaceutical company. The company says software carries virtually no manufacturing cost, which it presents as room for operating margin improvement.

If the discussions it describes with several global pharma companies lead to similar contracts, reliance on instrument sales could fall.

Standardization research and order flow

Kiwoom Securities said in June 2026 that the reproducibility shown at CYTO 2026 suggested a possible standard for the automated instruments. The company is taking part in a follow-up NIST study.

Reported orders include a KRW 500 million order from a global pharma company in August 2026 and a KRW 700 million first order from a global top-five CRO in October, indicating expansion among overseas customers.

Quarterly revenue recovery and loss movement

Third-quarter 2026 revenue of KRW 1.49 billion rose 7.8% year on year. The operating loss in the same quarter was KRW 3.92 billion, narrower than KRW 4.46 billion in the prior quarter. A wisereport aggregation shows first-half 2026 revenue up 30.3% year on year, indicating a gradually broadening revenue base.

09

Bear factors

Continued losses and wider net loss

The company has reported losses in each year from 2022 to 2025, with an operating loss of KRW 12.3 billion and a net loss of KRW 27.2 billion in 2025. The net loss attributable to controlling shareholders was KRW 5.31 billion in Q3 2026, wider than a year earlier.

The four quarters from Q4 2025 to Q3 2026 total KRW 15.1 billion in net losses, and operating cash flow was KRW -11.1 billion in 2025.

Stagnant instrument-driven revenue

Revenue went from KRW 7.24 billion in 2022 to KRW 5.15 billion in 2025 and has not returned to the 2022 level. Revenue declined in both Q1 and Q2 2026. Media coverage cites the instrument-centered model as a constraint on growth, and the three-year software target has not yet appeared in reported revenue figures.

Litigation and derivative valuation volatility

Media reported a sharp share price decline after the lawsuit over C-FREE-related technology was disclosed on November 12, 2026. The company cited a derivative valuation loss tied to the share price rise as the main driver of the wider 2025 net loss.

Because net results can swing with share price and convertible-right valuations, the interpretation of reported earnings carries high volatility.

10

Risk factors

Legal risk

On November 12, 2026, the company filed suit against Becton, Dickinson and Company and Waters Corporation over C-FREE-related technology. The company says the case is in court and it has no further comment for now.

The outcome could change the scope of protection for its core technology and the business environment, and litigation costs will affect reported results.

Derivative and convertible bond valuation swings

The company cited derivative valuation losses tied to convertible bond rights as the main reason for the 2025 net loss of KRW 27.2 billion. When the share price rises, valuation losses grow, and when it falls, valuation gains can appear, so net results can move regardless of operating performance.

A June 2026 disclosure on acquiring convertible bonds also points to continuing changes in the capital structure.

Dilution and major shareholder stake changes

As of April 16, 2026, CEO Kim Nam-yong and six related parties reported holding 17.84% of the shares. On March 31, 2026, the board granted stock options for 47,600 common shares, bringing the cumulative total to 309,558 common shares. While losses continue, exercises of these options and new share issuance could increase the share count.

11

What to watch next

  1. End of December 2026 (by year-end)

    Whether additional Pluto Code license contracts with global pharma companies are signed. The company said it is pursuing more agreements within the year, so this checks whether software contracts actually increase.

  2. End of December 2026 (by year-end)

    Whether the first partnership with a global instrument maker is signed. It shows whether a channel to expand both instrument distribution and software deployment actually opens.

  3. After November 2026 · court dates to be determined

    Progress of the C-FREE-related lawsuit against Becton, Dickinson and Company and Waters Corporation. A ruling or settlement could change the scope of protection for the core technology and the operating environment.

  4. Early February 2027 (estimated from last year's disclosure timing)

    Whether preliminary 2026 full-year operating results and revenue are disclosed. This is estimated from the February 5, 2026 disclosure of the 2025 change in revenue or profit structure.

  5. By March 31, 2027

    Filing of the 2026 annual business report, the next periodic report. The 2025 annual report was filed on March 23, 2026. The reported operating margin and any change in software-related revenue mix are the points to check.

12

Overall view

Curiox Biosystems' disclosed results show revenue signs of recovery alongside continued losses. Revenue rose 12.3% to KRW 5.15 billion in 2025, but the operating loss of KRW 12.3 billion and net loss of KRW 27.2 billion show the loss structure remains.

Third-quarter 2026 revenue of KRW 1.49 billion rose 7.8% year on year, while the net loss attributable to controlling shareholders widened to KRW 5.31 billion. The company says a non-operating factor, a derivative valuation loss tied to the share price rise, contributed heavily to the wider 2025 net loss.

On the business side, the shift from instrument-centered revenue to software licensing is under way, with the April 2026 comprehensive license as the first case. Strengths include the potential for software revenue growth, standardization research results, and first-half 2026 revenue growth.

Weaknesses include operating losses in five consecutive quarters, a combined net loss of KRW 15.1 billion over the last four quarters, and the lawsuit disclosed in November 2026.

The next checkpoints are whether additional license contracts are signed by year-end 2026 and the operating margin in the 2026 annual business report due by March 31, 2027.

13

Sources

  1. Korea Exchange (KRX) — Prices · Market Cap · Volume
  2. FSS electronic disclosure system (DART) — Financial statements · Dividend filings
Show 17 more articles and sources
  1. curiox.co.kr
  2. comp.wisereport.co.kr
  3. news.nate.com
  4. curiox.co.kr
  5. comp.fnguide.com
  6. saramin.co.kr
  7. m.news.nate.com
  8. curiox.co.kr
  9. butler.works
  10. m.irgo.co.kr
  11. news.nate.com
  12. news.nate.com
  13. digitaltoday.co.kr
  14. m.news.nate.com
  15. job-post.co.kr
  16. news.nate.com
  17. edaily.co.kr

Report written 2026-11-18 · Data as of 2026-11-17

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.

Other reports in this industry

View industry analysis